Mechanisms of resistance to molecular targeted therapies in breast cancer: Update and future;Mécanismes de résistance aux thérapeutiques moléculaires ciblées dans le cancer du sein: Constats et perspectives

Bulletin du Cancer

Volumn 97, Issue 3, 2010, Pages 385-395

  Magne N ^a   Chargari, C ^b   Conforti, R ^a   Toillon, R A ^c   Bauduceau, O ^b   Vedrine L ^b   Khayat, D ^a   Spano, J P ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b University of Paris Descartes   (France)

^c INSERM   (France)

Author keywords

Bevacizumab; Breast cancer; Resistance; Targeted therapy; Trastuzumab

Indexed keywords

4 [3 CHLORO 4 (2 PYRIDINYLMETHOXY)ANILINO] 3 CYANO 6 (4 DIMETHYLAMINOCROTONAMIDO) 7 ETHOXYQUINOLINE; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CANERTINIB; CETUXIMAB; CP 751851; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; N [4 (3 CHLORO 4 FLUOROANILINO) 7 (TETRAHYDRO 3 FURYLOXY) 6 QUINAZOLINYL] 4 DIMETHYLAMINO 2 BUTENAMIDE; PERTUZUMAB; SORAFENIB; SUNITINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY; TUMOR PROTEIN;

BREAST CANCER; CANCER PATIENT; CANCER RESISTANCE; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; PROTEIN EXPRESSION; REVIEW; TREATMENT OUTCOME; TUMOR CELL; BREAST TUMOR; DRUG ANTAGONISM; DRUG POTENTIATION; DRUG RESISTANCE; FEMALE; METABOLISM; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HUMANS; NEOPLASM PROTEINS; RECEPTOR, ERBB-2;

EID: 77950351216     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2010.1051     Document Type: Review

References (91)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 1987 ; 235 : 177-182
2. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001 ; 344 : 783-792 (Pubitemid 32222155)
3. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005 ; 23 : 4265-4274 (Pubitemid 46207001)
4. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl JMed 2005 ; 353 : 1659-1672 (Pubitemid 41464705)
5. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer Jr CE, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005 ; 353 : 1673-1684 (Pubitemid 41464706)
6. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, et al. Two-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007 ; 369 : 29-36. (Pubitemid 46039831)
7. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006 ; 354 : 809-820 (Pubitemid 43290919)
8. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006 ; 66 : 1630-1639 (Pubitemid 43259947)
9. Burris 3rd HA, Hurwitz HI, Dees EC, Dowlati A, Blackwell KL, O'Neil B, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine-kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005 ; 23 : 5305-5313
10. Coulibaly JD, Effi AB, Horo GA, Diabate A, Mbra K, Adoubi I, et al. Hormonal status and overexpression of HER2 in breast cancer, cancerology department of Treichville UHC. Preliminary results. Bull Cancer 2008 ; 95 : 799-803.
11. Penault-Llorca F. Targeted therapies: the question of target detection and evaluation. Bull Cancer 2007 ; 94 : F245-8. (Pubitemid 350131952)
12. Fumoleau P, Campone M, Coudert B, Mayer F, Favier L, Ferrant E. Targeting ErbB receptors in breast cancer. Bull Cancer 2007 ; 94 : F147-50.
13. Fumoleau P, Coudert B, Mayer F, Isambert N, Favier L, Ferrant E. Angiogenesis targeting in breast cancer. Bull Cancer 2007 ; 94 : F199-206.
14. Magné N, Milano G. Targeted therapies: last focus on EGF receptor inhibitors in breast cancer. Bull Cancer 2004 ; 91 : S257-60.
15. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007 ; 357 : 2666-2676
16. Bauvet F, Awada A, Gil T, Hendlisz A. Therapeutic consequences of molecular biology advances in oncology. Bull Cancer 2009 ; 96 : 59-71.
17. Milano G. Design of new protocols. Role of molecular biology units? Bull Cancer 2008 ; 95 : 1003-1005
18. Spano JP. Targeted therapy: what does it mean? A physician point of view. Bull Cancer 2007 ; 94 : F111-4.
19. Dieras V, Vincent-Salomon A, Degeorges A, Beuzeboc P, Mignot L, de Cremoux P. Trastuzumab (Herceptin) and breast cancer: mechanisms of resistance. Bull Cancer 2007 ; 94 : 259-266 (Pubitemid 46586778)
20. Bedard PL, Cardoso F, Piccart-Gebhart MJ. Stemming resistance to HER2 targeted therapy. J Mammary Gland Biol Neoplasia 2009 ; 14 : 55-66.
21. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004 ; 6 : 117-127 (Pubitemid 39485684)
22. Lane HA, Motoyama AB, Beuvink I, Hynes NE. Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling. Ann Oncol 2001 ; 12 : S21-2. (Pubitemid 32750580)
23. Coudert BP, Largillier R, Arnould L, Chollet P, Campone M, Coeffic D, et al. Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial. J Clin Oncol 2007 ; 25 : 2678-2684 (Pubitemid 47123173)
24. Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytoxicity mechanism? Br J Cancer 2006 ; 94 : 259-267
25. Lu CH, Wyszomierski SL, Tseng LM, Sun MH, Lan KH, Neal CL, et al. Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res 2007 ; 13 : 5883-5888
26. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER2/neu-positive metastatic breast cancer. J Clin Oncol 2008 ; 26 : 1789-1796
27. Mohsin SK, Weiss HL, Gutierrez MC, Chamness GC, Schiff R, Digiovanna MP, et al. Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol 2005 ; 23 : 2460-2468 (Pubitemid 47050836)
28. Fleishman SJ, Schlessinger J, Ben-Tal N. A putative molecular-activation switch in the transmembrane domain of erbB2. Proc Natl Acad Sci USA 2002 ; 99 : 15937-15940 (Pubitemid 35462727)
29. Marhaba R, Zöller M. CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol 2004 ; 35 : 211-231 (Pubitemid 40585308)
30. Nagy P, Friedländer E, Tanner M, Kapanen AI, Carraway KL, Isola J, et al. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res 2005 ; 65 : 473-482
31. Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL. Epidermal growth factor receptor (HER1) tyrosinekinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (ErbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 2001 ; 61 : 8887-8895 (Pubitemid 34013905)
32. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor 1 receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001 ; 93 : 1852-1857.
33. Diermeier S, Horváth G, Knuechel-Clarke R, Hofstaedter F, Szöllosi J, Brockhoff G. Epidermal growth factor receptor coexpression modulates susceptibility to herceptin in HER2/neu overexpressing breast cancer cells via specific ErbB-receptor interaction and activation. Exp Cell Res 2005 ; 304 : 604-619 (Pubitemid 40321136)
34. Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ. Insulin-like growth factor 1 receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 2005 ; 65 : 11118-11128 (Pubitemid 41713383)
35. Scaltriti M, Rojo F, Ocaña A, Anido J, Guzman M, Cortes J, et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 2007 ; 99 : 628-638 (Pubitemid 47073544)
36. Parsons R, Simpson L. PTEN and cancer. Methods Mol Biol 2003 ; 222 : 147-166
37. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007 ; 12 : 395-402. (Pubitemid 47539306)
38. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev 1999 ; 13 : 2905-2927
39. Kang SS, Kwon T, Kwon DY, Do SI. Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit. J Biol Chem 1999 ; 274 : 13085-13090 (Pubitemid 129518508)
40. Clark AS, West K, Streicher S, Dennis PA. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 2002 ; 1 : 707-717
41. Alkarain A, Slingerland J. Deregulation of p27 by oncogenic signaling and its prognostic significance in breast cancer. Breast Cancer Res 2004 ; 6 : 13-21. (Pubitemid 38195556)
42. Descamps S, Pawlowski V, Révillion F, Hornez L, Hebbar M, Boilly B, et al. Expression of nerve growth factor receptors and their prognostic value in human breast cancer. Cancer Res 2001 ; 61 : 4337-4340 (Pubitemid 32685755)
43. Descamps S, Toillon RA, Adriaenssens E, Pawlowski V, Cool SM, Nurcombe V, et al. Nerve growth factor stimulates proliferation and survival of human breast cancer cells through two distinct signaling pathways. J Biol Chem 2001 ; 276 : 17864-17870 (Pubitemid 37411345)
44. Lagadec C, Adriaenssens E, Meignan S, Vanhecke E, Romon R, Toillon RA, et al. TrkA overexpression enhances growth and metastasis of breast cancer cells. Oncogene 2009 ; 28 : 1960-1970
45. Tagliabue E, Castiglioni F, Ghirelli C, Modugno M, Asnaghi L, Somenzi G, et al. Nerve growth factor cooperates with p185HER2 in activating growth of human breast carcinoma cells. J Biol Chem 2000 ; 275 : 5388-5394 (Pubitemid 30115169)
46. Festuccia C, Gravina GL, Muzi P, Millimaggi D, Dolo V, Vicentini C, et al. HER2 crosstalks with TrkA in a subset of prostate cancer cells: rationale for a guided dual treatment. Prostate 2009 ; 69 : 337-345
47. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006 ; 355 : 2733-2743 (Pubitemid 46021510)
48. Gomez HL, Doval DC, Chavez MA, Anq PC, Aziz Z, Naq S, et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 2008 ; 26 : 2999-3005.
49. Kaufman B, Trudeau M, Awada A, Blackwell K, Bachelot T, Salazar V, et al. Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2-positive cohort in EGF103009, a phase II study. Lancet Oncol 2009 ; 10 : 581-588
50. Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB2 tyrosine-kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001 ; 1 : 85-94.
51. Nahta R, Esteva FJ. Trastuzumab: triumphs and tribulations. Oncogene 2007 ; 28 : 3626-3637
52. Xia W, Husain I, Liu L, Bacus S, Saini S, Spohn J, et al. Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers. Cancer Res 2007 ; 67 : 1170-1175 (Pubitemid 46270775)
53. Moasser MM, Basso A, Averbuch SD, Rosen N. The tyrosinekinase inhibitor ZD1839 "Iressa" inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 2001 ; 61 : 7184-7188
54. Moulder S, O'Neill A, Arteaga C, Pins M, Sparano J, Sledge G, et al. Final results of ECOG1100: a phase I/II study of combined blockade of the ErbB receptor network in patients with HER2 overexpressing metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2007 (Abstract 1033).
55. Rabidran SK, Discafani CM, Rosfjord EC, Baxter M, Floyd MB, Golas J, et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER2 tyrosine-kinase. Cancer Res 2004 ; 64 : 3965-3985 (Pubitemid 38697310)
56. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW, et al.. Structure of the extracellular region of HER alone and in complex with Herceptin Fab. Nature 2003 ; 421 : 756-760
57. Modi S, Sugarman S, Stopeck A, Linden H, Ma W, Kersey K, et al. Phase II trial of the Hsp90 inhibitor tanespimycin (Tan) + trastuzumab (T) in patients with HER2-positive metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2008 (Abstract 1027).
58. Eichhorn PJA, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W, et al. Phosphatydilinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatydilinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 2008 ; 68 : 9221-9230
59. Jerusalem GH, Dieras V, Cardoso F, Bergh J, Fasolo A, Rorive A, et al. Multicenter phase I clinical trial of daily and weekly RAD001 in combination with vinorelbine and trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab. Proc Am Soc Clin Oncol 2008 (Abstract 1057).
60. Kiewe P, Hasmüller S, Kahlert S, Heinrigs M, Rack B, Marmé A, et al. Phase I trial of the trifunctional anti-HER anti-CD3 antibody ertumaxomab (rexomum) in metastatic breast cancer cancer. Proc Am Soc Clin Oncol 2007 (Abstract 2530).
61. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008 ; 68 : 9280-9290
62. Fumoleau P, Coudert B, Mayer F, Isambert N, Favier L, Ferrant E. Angiogenesis targeting in breast cancer. Bull Cancer 2007 ; 94 : F199-F206.
63. Ruegg C, Mutter N. Antiangiogenic therapies in cancer: achievements and open questions. Bull Cancer 2007 ; 94 : 753-762 (Pubitemid 47605603)
64. Bachelot T, Ray-Coquard I, Cassier P, Blay JY. Angiogenesis and breast cancer. Bull Cancer 2007 ; 94 : S203-10.
65. Ray-Coquard I, Bachelot T, Saba C, Confavreux C, Brantus JF, Rustam F, et al. Are antiangiogenic antibodies universal for solid tumor? Bull Cancer 2007 ; 94 : 191-196
66. Lauzier MC, Michaud MD, Déry MA, Richard DE. HIF-1 activation during tumor progression: implications and consequences. Bull Cancer 2006 ; 93 : 349-356 (Pubitemid 43742483)
67. Bando H. Vascular endothelial growth factor and bevacizumab in breast cancer. Breast Cancer 2007 ; 14 : 163-173
68. Toi M, Matsumoto T, Bando H. Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications. Lancet Oncol 2001 ; 2 : 667-673 (Pubitemid 33085812)
69. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007 ; 357 : 2666-2676
70. Robert NJ, Dieras V, Glaspy J, Brufsky A, Bondarenko I, Lipatov O, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of HER-2 negative locally recurrent or metastatic breast cancer. Proc Am Soc Clin Oncol 2009 (Abstract 1005).
71. Dal Lago L, D'Hondt V, Awada A. Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors. Oncologist 2008 ; 13 : 845-858
72. Kerbel RS. A cancer therapy resistant to resistance. Nature 1997 ; 390 : 335-336
73. Ademuyiwa FO, Miller KD. Incorporation of antiangiogenic therapies in the treatment of metastatic breast cancer. Clin Breast Cancer 2008 ; 8 : 151-156
74. Relf M, LeJeune S, Scott PA, Fox S, Smith K, Leek R, et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997 ; 57 : 963-969 (Pubitemid 27098025)
75. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, et al. Role of HIF-1 in hypoxiamediated apoptosis, cell proliferation and tumor angiogenesis. Nature 1998 ; 394 : 485-490 (Pubitemid 28373960)
76. Brown EB, Campbell RB, Tsuzuki Y, Xu L, Carmeliet P, Fukumura D, et al. In vivo measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy. Nature Med 2001 ; 7 : 864-868
77. Pozzi A, Moberg PE, Miles LA,Wagner S, Soloway P, Gardner HA. Elevated matrix metalloprotease and angiostatin levels in integrin alpha-1 knockout mice cause reduced tumor vascularization. Proc Natl Acad Sci USA 2000 ; 97 : 2202-2207 (Pubitemid 30134046)
78. Hattori K, Dias S, Heissig B, Hackett NR, Lyden D, Tateno M, et al. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J Exp Med 2001 ; 193 : 1005-1014 (Pubitemid 32436194)
79. Folberg R, Hendrix MJ, Maniotis AJ. Vasculogenic mimicry and tumor angiogenesis. Am J Pathol 2000 ; 156 : 361-381
80. Kakeji Y, Maehara Y, Ikebe M, Teicher BA. Dynamics of tumor oxygenation, CD31 staining and transforming growth factor-β levels after treatment with radiation or cyclophosphamide in the rat 13762 mammary carcinoma. Int J Radiat Oncol Biol Phys 1997 ; 37 : 1115-1123 (Pubitemid 27230037)
81. Fogler W, Song M, Supko J, et al. Recombinant human endostatin demonstrates consistent and predictable pharmacokinetics following intravenous bolus administration to cancer patients. Proc Am Soc Clin Oncol 2001 (Abstract 279).
82. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000 ; 60 : 1878-1886 (Pubitemid 30207647)
83. Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK, Shen J, et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 2001 ; 61 : 3369-3372 (Pubitemid 32695027)
84. Bachelder RE, Crago A, Chung J, Chung J, Wendt MA, Shaw LM, et al. Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res 2001 ; 61 : 5736-5740 (Pubitemid 32769088)
85. Scappaticci FA, Smith R, Pathak A, Schloss D, Lum B, Cao Y, et al. Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity in vitro and antitumor efficacy in leukemia and solid tumors in mice. Mol Ther 2001 ; 3 : 186-196 (Pubitemid 32509821)
86. Rak J, Yu JL, Klement G, Kerbel RS. Oncogenes and angiogenesis: signaling three-dimensional tumor growth. J Investig Dermatol Symp Proc 2000 ; 5 : 24-33. (Pubitemid 32044086)
87. Petit AM, Rak J, Hung MC, Rockwell P, Goldstein N, Fendly B, et al. Neutralizing antibodies against epidermal growth factor and ErbB2/neu receptor tyrosine-kinases downregulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997 ; 151 : 1523-1530 (Pubitemid 27527914)
88. Koukourakis MI, Giatromanolaki A, O'Byrne KJ, Cox J, Krammer B, Gatter KC, et al. bcl-2 and c-erbB-2 proteins are involved in the regulation of VEGF and of thymidine phosphorylase angiogenic activity in non-small-cell lung cancer. Clin Exp Metastasis 1999 ; 17 : 545-554 (Pubitemid 30337128)
89. Hynes NE, Lane HA. ErbB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005 ; 5 : 341-354
90. Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine-kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008 ; 26 : 1810-1816
91. ALTTO: Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation Trial. A randomised, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in women with HER2 (ErbB2) positive primary breast cancer (BIG 2-06/N06D/EGF106708). ALTTOtrials@bordet.be. www.breastinternationalgroup.org.